These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 24161074)
1. Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft. Nee R; Parker AL; Little DJ; Yuan CM; Himmelfarb J; Lowe SR; Abbott KC Clin Nephrol; 2014 Jan; 81(1):38-51. PubMed ID: 24161074 [TBL] [Abstract][Full Text] [Related]
2. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944 [TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. Kourlaba G; Fragoulakis V; Maniadakis N Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. Chambers M; Hutton J; Gladman J Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness Analysis of Vascular Access Referral Policies in CKD. Shechter SM; Chandler T; Skandari MR; Zalunardo N Am J Kidney Dis; 2017 Sep; 70(3):368-376. PubMed ID: 28599902 [TBL] [Abstract][Full Text] [Related]
9. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations. Logman JF; Heeg BM; Herlitz J; van Hout BA Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780 [TBL] [Abstract][Full Text] [Related]
10. Patency in arteriovenous grafts in hemodialysis patients. Mousa AY; Patterson W; Abu-Halimah S; Hass SM; Alhalbouni S; Sadek BT; Nanjundappa A; Modak A; Stone PA; Emmett M; AbuRahma AF Vasc Endovascular Surg; 2013 Aug; 47(6):438-43. PubMed ID: 23853221 [TBL] [Abstract][Full Text] [Related]
11. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Schleinitz MD; Weiss JP; Owens DK Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495 [TBL] [Abstract][Full Text] [Related]
12. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Haentjens P; De Groote K; Annemans L Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin receptor blockers and antiplatelet agents are associated with improved primary patency after arteriovenous hemodialysis access placement. Jackson RS; Sidawy AN; Amdur RL; Khetarpal A; Macsata RA J Vasc Surg; 2011 Dec; 54(6):1706-12. PubMed ID: 21840155 [TBL] [Abstract][Full Text] [Related]
14. Antiplatelet therapy and vascular-access patency. Lok CE N Engl J Med; 2009 May; 360(21):2240-2. PubMed ID: 19458370 [No Abstract] [Full Text] [Related]
15. Dipyridamole plus aspirin and hemodialysis graft patency. Hentschel DM N Engl J Med; 2009 Aug; 361(7):720-1; author reply 721. PubMed ID: 19681176 [No Abstract] [Full Text] [Related]
16. Dipyridamole plus aspirin and hemodialysis graft patency. Weale AR; Cooper DG N Engl J Med; 2009 Aug; 361(7):720; author reply 721. PubMed ID: 19675337 [No Abstract] [Full Text] [Related]
17. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Lindgren P; Stenestrand U; Malmberg K; Jönsson B Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611 [TBL] [Abstract][Full Text] [Related]
18. Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study. Conte MS; Nugent HM; Gaccione P; Guleria I; Roy-Chaudhury P; Lawson JH J Vasc Surg; 2009 Dec; 50(6):1359-68.e1. PubMed ID: 19958986 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of vascular access for haemodialysis: arteriovenous fistulas versus arteriovenous grafts. Leermakers JJ; Bode AS; Vaidya A; van der Sande FM; Evers SM; Tordoir JH Eur J Vasc Endovasc Surg; 2013 Jan; 45(1):84-92. PubMed ID: 23153926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]